“I was very afraid when I saw the alert on the shortage of Quétiapine, which started in my pharmacy [en Charente-Maritime] From September 2024testifies Emilie (she requested anonymity), a member of the association for helping people with bipolar disorders and their relatives (Argos 2001). Because quetiapine is the only treatment that works for me. »»
The forties was diagnosed with bipolar in 2016, after years of wandering. “Lithium, Tegretol, Depakote (valproate) … I took all these mood regulators. None were walking. »» Except the prolonged liberation quetiapine, which is subject to “Strong supply tensions”as Actuate the National Medicines Safety Agency (ANSM) three times since the beginning of 2025.
Enough to put on professional health alert and patient associations, while this treatment, registered on the so -called essential drugs, is prescribed for 250,000 people to treat bipolar disorders and schizophrenia.
The shortages now affect “60 % of the French market”said the drug agency in its latest statement on Monday, March 10. “We face a real lack of visibility” and at “Big uncertainties” Regarding his discount, explains Pierre-Olivier Farenq, director of the agency’s risk support center.
You have 82.58% of this article to read. The rest is reserved for subscribers.